Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 USD | -3.00% | -4.47% | -12.48% |
May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
Apr. 29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
Financials (USD)
Sales 2024 * | 115K | Sales 2025 * | 2.57M | Capitalization | 19.59M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -25M | EV / Sales 2024 * | 170 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.62 x |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-0.85
x | Employees | 27 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.07% |
Latest transcript on AIM ImmunoTech Inc.
1 day | -3.00% | ||
1 week | -4.47% | ||
Current month | -5.75% | ||
1 month | -10.47% | ||
3 months | -7.81% | ||
6 months | -10.40% | ||
Current year | -12.48% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 0.385 | -3.00% | 164,681 |
24-05-23 | 0.3969 | -3.31% | 123,802 |
24-05-22 | 0.4105 | +0.12% | 178,825 |
24-05-21 | 0.41 | -1.18% | 81,232 |
24-05-20 | 0.4149 | +2.95% | 175,278 |
Delayed Quote Nyse, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.48% | 19.59M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AIM Stock